Cargando…

Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis

We describe a human nasal epithelial (HNE) organoid model derived directly from patient samples that is well-differentiated and recapitulates the airway epithelium, including the expression of cilia, mucins, tight junctions, the cystic fibrosis transmembrane conductance regulator (CFTR), and ionocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhongyu, Anderson, Justin D., Deng, Lily, Mackay, Stephen, Bailey, Johnathan, Kersh, Latona, Rowe, Steven M., Guimbellot, Jennifer S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349680/
https://www.ncbi.nlm.nih.gov/pubmed/32485957
http://dx.doi.org/10.3390/genes11060603
_version_ 1783557110869524480
author Liu, Zhongyu
Anderson, Justin D.
Deng, Lily
Mackay, Stephen
Bailey, Johnathan
Kersh, Latona
Rowe, Steven M.
Guimbellot, Jennifer S.
author_facet Liu, Zhongyu
Anderson, Justin D.
Deng, Lily
Mackay, Stephen
Bailey, Johnathan
Kersh, Latona
Rowe, Steven M.
Guimbellot, Jennifer S.
author_sort Liu, Zhongyu
collection PubMed
description We describe a human nasal epithelial (HNE) organoid model derived directly from patient samples that is well-differentiated and recapitulates the airway epithelium, including the expression of cilia, mucins, tight junctions, the cystic fibrosis transmembrane conductance regulator (CFTR), and ionocytes. This model requires few cells compared to airway epithelial monolayer cultures, with multiple outcome measurements depending on the application. A novel feature of the model is the predictive capacity of lumen formation, a marker of baseline CFTR function that correlates with short-circuit current activation of CFTR in monolayers and discriminates the cystic fibrosis (CF) phenotype from non-CF. Our HNE organoid model is amenable to automated measurements of forskolin-induced swelling (FIS), which distinguishes levels of CFTR activity. While the apical side is not easily accessible, RNA- and DNA-based therapies intended for systemic administration could be evaluated in vitro, or it could be used as an ex vivo biomarker of successful repair of a mutant gene. In conclusion, this highly differentiated airway epithelial model could serve as a surrogate biomarker to assess correction of the mutant gene in CF or other diseases, recapitulating the phenotypic and genotypic diversity of the population.
format Online
Article
Text
id pubmed-7349680
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73496802020-07-15 Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis Liu, Zhongyu Anderson, Justin D. Deng, Lily Mackay, Stephen Bailey, Johnathan Kersh, Latona Rowe, Steven M. Guimbellot, Jennifer S. Genes (Basel) Article We describe a human nasal epithelial (HNE) organoid model derived directly from patient samples that is well-differentiated and recapitulates the airway epithelium, including the expression of cilia, mucins, tight junctions, the cystic fibrosis transmembrane conductance regulator (CFTR), and ionocytes. This model requires few cells compared to airway epithelial monolayer cultures, with multiple outcome measurements depending on the application. A novel feature of the model is the predictive capacity of lumen formation, a marker of baseline CFTR function that correlates with short-circuit current activation of CFTR in monolayers and discriminates the cystic fibrosis (CF) phenotype from non-CF. Our HNE organoid model is amenable to automated measurements of forskolin-induced swelling (FIS), which distinguishes levels of CFTR activity. While the apical side is not easily accessible, RNA- and DNA-based therapies intended for systemic administration could be evaluated in vitro, or it could be used as an ex vivo biomarker of successful repair of a mutant gene. In conclusion, this highly differentiated airway epithelial model could serve as a surrogate biomarker to assess correction of the mutant gene in CF or other diseases, recapitulating the phenotypic and genotypic diversity of the population. MDPI 2020-05-29 /pmc/articles/PMC7349680/ /pubmed/32485957 http://dx.doi.org/10.3390/genes11060603 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Zhongyu
Anderson, Justin D.
Deng, Lily
Mackay, Stephen
Bailey, Johnathan
Kersh, Latona
Rowe, Steven M.
Guimbellot, Jennifer S.
Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title_full Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title_fullStr Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title_full_unstemmed Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title_short Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
title_sort human nasal epithelial organoids for therapeutic development in cystic fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349680/
https://www.ncbi.nlm.nih.gov/pubmed/32485957
http://dx.doi.org/10.3390/genes11060603
work_keys_str_mv AT liuzhongyu humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT andersonjustind humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT denglily humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT mackaystephen humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT baileyjohnathan humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT kershlatona humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT rowestevenm humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis
AT guimbellotjennifers humannasalepithelialorganoidsfortherapeuticdevelopmentincysticfibrosis